Cure Today6d
Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma
Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...
pharmaphorum2y
Keytruda encroaches on Jemperli's endometrial cancer territory
Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...
pharmaphorum2d
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...
Cure Today6d
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...
oncnursingnews6d
Certain AEs May Indicate Improved PFS With Enfortumab Vedotin for Urothelial Carcinoma
Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.